Background: We evaluated the clinical performance of [-2]proPSA (p2PSA) and its derivatives in predicting the presence and aggressiveness of prostate cancer (PCa) in Korean men. Methods: A total of 246 men with total prostate-specific antigen (tPSA) ≥ 3.5 ng/mL who underwent their first prostate biopsy were included in this prospective, multicenter, observational study. Diagnostic accuracy of tPSA, free-to-total PSA ratio (%fPSA), p2PSA, %p2PSA, and the Beckman Coulter prostate health index (PHI) was assessed by receiver operating characteristic curve analyses and logistic regression analyses. Results: Overall, PCa was detected in 125 (50.8%) subjects. In men with tPSA 3.5-10 ng/mL, the detection rate of PCa was 39.4% (61/155). In this group, PHI and %p2PSA were the most accurate predictors of PCa and significantly outperformed tPSA and %fPSA; area under the curve for tPSA, %fPSA, %p2PSA, and PHI was 0.56, 0.69, 0.74, and 0.76, respectively. PHI was also the strongest predictor of PCa with Gleason score ≥ 7. Conclusion: This study demonstrates the superior clinical performance of %p2PSA and PHI in predicting the presence and aggressiveness of PCa in Korean men. The %p2PSA and PHI appear to improve detection of PCa and provide prognostic information.
INTRODUCTION
Prostate-specific antigen (PSA) is widely accepted as a tumor marker for the screening, diagnosis, monitoring, and risk prediction of prostate cancer (PCa). 1, 2 The introduction of PSA has resulted in a stage migration to clinically localized disease and a reduction in mortality. Although two recent randomized trials evaluating the effect of PSA-based screening on mortality reduction reported conflicting results, PSA screening appears to provide oncologic benefit. 3, 4 However, PSA has limitations as a screening biomarker. First, it is organ specific and not cancer specific. 5 It also lacks sensitivity. In addition, PSA cannot distinguish between transrectal ultrasonography (TRUS). All patients underwent TRUS-guided prostate biopsies according to a standardized scheme not using magnetic resonance imaging (MRI); at least 12 biopsy cores were taken, with additional cores taken if the performing radiologist felt more cores were needed for adequate sampling. The specimens were processed and evaluated by a single experienced genitourinary pathologist, who was blinded to the test results. PCa was identified and graded according to the 2005 consensus conference of the International Society of Urological Pathology definitions. 17 
Study end points
The primary end point was the diagnostic accuracy of serum %p2PSA ([p2PSA pg/mL]/(fPSA ng/mL × 1,000)] × 100) and Beckman Coulter PHI, and a comparison of their performance with the established biomarkers (tPSA and %fPSA) in determining the presence of PCa at prostate biopsy. The secondary end point was the predictive value of these serum indices for aggressive PCa with Gleason score (GS) ≥ 7.
Statistical analyses
The Kolmogorov-Smirnov test was used to assess the normal distribution of variables. Student's t-test and the Mann-Whitney U test were used for comparisons of normally and not normally distributed continuous variables, respectively. Bivariate and multivariate logistic regression models were fitted for the prediction of the presence of PCa and, in particular, PCa with GS ≥ 7 at biopsy. Goodness of fit of logistic regression models was checked using the Hosmer and Lemeshow test. Odds ratios with 95% confidence intervals were also calculated. Qualitative data were analyzed with the χ 2 test.
Multivariate logistic regression models were complemented by predictive accuracy analyses. Predictive accuracy was quantified as the area under the receiver operating characteristic curve (AUC). To test the ability of %p2PSA and PHI in determining the presence of PCa at biopsy, these variables were added to the base multivariate model including age, prostate volume, tPSA, and %fPSA. The increase in predictive accuracy was quantified and AUCs were compared using the DeLong method. 18 The correlation between variables was tested using the Spearman's rho coefficient analysis. Statistical analyses were performed with SPSS Statistics version 21.0 (SPSS, Chicago, IL, USA). Statistical significance was considered at P < 0.05.
Ethics statement
This study was approved by the Institutional Review Board (IRB) of each institution (approval number of Kangwon National University Hospital: KNUH 2015-04-004-001). The study protocol and the use of patient data for recruitment and follow-up were approved by the IRB of each institution before patient recruitment. All participants provide their written informed consent to participate in this study.
RESULTS
From June 2015 to August 2016, 280 men underwent their first prostate biopsy at the four institutions. Of these, 246 patients were included in this study. Among the overall subjects, 155 men belonged to the subgroup with tPSA 3.5-10 ng/mL. Performance of p2PSA and Prostate Health Index patients diagnosed with PCa, 40 (32.0%) had GS 6 disease, 68 (54.4%) had GS 7 disease, and 17 (13.6%) had GS 8-10 disease. Compared to the negative biopsy group, age, tPSA, %p2PSA, and PHI were significantly higher in patients with PCa. On the contrary, prostate volume and %fPSA were higher in patients without PCa.
Descriptive characteristics of the 155 subjects with tPSA 3.5-10 ng/mL are summarized in Table 2 . The positive biopsy rate was 39.3% (61/155). In this subgroup with tPSA 3.5-10 ng/ mL, mean age (69.6 vs. 67.3 years, P = 0.09) and median tPSA (6.2 vs. 5.9 ng/mL, P = 0.24) did not differ significantly between men with and those without PCa. In contrast, %p2PSA (1.7 vs. 1.2) and PHI (42.7 vs. 26.5) values were significantly higher (both P < 0.001) in men with PCa. Conversely, %fPSA (0.12 vs. 0.19, P < 0.001) and prostate volume (33 vs. 46 mL, P = 0.002) were statistically significantly lower in patients with PCa.
In the whole population of 246 men, the AUC for tPSA, %fPSA, %p2PSA, and PHI was 0.683, 0.681, 0.761, and 0.797, respectively. The AUC of the subgroup with tPSA 3.5-10 ng/mL was 0.556, 0.685, 0.740, and 0.763, respectively ( Fig. 1) . On univariate analysis, PHI was most accurate in predicting the results of the initial biopsy. PHI significantly outperformed tPSA and %fPSA, but not %p2PSA (P = 0.149) in the prediction of PCa. %p2PSA also significantly outperformed tPSA and %fPSA in the prediction of PCa (P < 0.001).
In the subgroup of patients with tPSA 3.5-10 ng/mL, multivariate logistic regression analyses also revealed that both PHI and %p2PSA were strong independent predictors, and that PHI significantly improved the predictive accuracy of a model including age, prostate volume, tPSA, and %fPSA ( Table 3) . To further assess the performance of the various parameters, we analyzed the data at a preset sensitivity level of 90%. At this sensitivity, PHI had the highest ), median (range), or number (%). SD = standard deviation, PSA = prostate-specific antigen, tPSA = total PSA, fPSA = free PSA, p2PSA = [-2]proPSA, PHI = prostate health index, GS = Gleason score. specificity of 68.3% while the specificity of tPSA was 21.2%. At a PHI cut-off of 22.9, 33 (21.3%) of 155 patients could have avoided undergoing a biopsy, while two patients with PCa would have been missed. However, no patient with GS 7 or greater would have been missed. Table 4 presents the comparison data between GS 6 disease and more aggressive disease. The PCa patients were divided into two groups according to the tumor aggressiveness (biopsy GS). PHI was also the strongest predictor of PCa with GS ≥ 7 ( Table 5 cancer increased with the PHI score (Fig. 2) . At the highest PHI interval (PHI > 80), there was 98.4% of chance of positive biopsy with GS ≥ 7. The Spearman's rho coefficient analysis demonstrated a strong positive correlation between GS and PHI level (rho 0.757, P < 0.001). ), median (range), or number (%). SD = standard deviation, PSA = prostate-specific antigen, tPSA = total PSA, fPSA = free PSA, p2PSA = [-2]proPSA, PHI = prostate health index, GS = Gleason score, PCa = prostate cancer. 
DISCUSSION
The ideal biomarkers for PCa need to be able to distinguish PCa from benign prostatic conditions and to differentiate between aggressive and indolent cancers. 1 The inherent limitations of PSA have spurred intensive efforts for alternative PCa biomarkers that are noninvasive and have improved accuracy and risk stratification properties. 2, 6 A growing armamentarium of novel PCa biomarkers has emerged in recent years. FDA-approved biomarkers include PHI, which is intended to distinguish cancerous and benign prostatic conditions in men ≥ 50 years of age with normal digital rectal examination results and tPSA levels of 4-10 ng/mL. This test determines the need of biopsy, thereby reducing unnecessary biopsies. 1,2 PHI is reportedly capable of detecting PCa with a greater specificity than tPSA and %fPSA, with more power in discriminating high grade (GS ≥ 7) cancer from low grade cancer. 11- 13 A meta-analysis has demonstrated that %p2PSA and PHI are consistently more accurate than standard reference tests in predicting prostate biopsy outcome and can guide decision making about prostate biopsy. 19 Our prospective study reinforces the evidence that both %p2PSA and PHI are significantly more accurate in predicting the presence of PCa at initial biopsy compared to tPSA and %fPSA. The inclusion of %p2PSA or PHI in a multivariate logistic regression model resulted in significant increase of its predictive accuracy. At a biopsy threshold of PHI > 22.9, 21.3% (33/155) of biopsies would have been avoided with no potentially aggressive cancer (GS ≥ 7) missed in patients with a tPSA range of 3.5-10 ng/mL. In other studies with similar results, at a cut-off for biopsy of PHI levels 25-32, 15.5%-45.2% of their cohorts could have avoided unnecessary biopsy; however, they would have missed 1.1%-3.8% of GS ≥ 7 PCa. 13,20, 21 Although there is no consensus on the PHI cut-off for biopsy, lowering the cut-off level would be more prudent to avoid missing high grade PCa.
In the current study, PHI was also associated with more aggressive PCa and could increase the accuracy of the base model for predicting GS ≥ 7 PCa. The proportion of aggressive cancer increased with the PHI score. Similarly, a European prospective study showed that PHI was able to improve the prediction of GS ≥ 7 PCa, 22 although the results did not achieve statistical significance due to the relatively small number of patients. Given these results, it appears that PHI could serve as a guide for men who wish to be treated only if there is aggressive PCa.
There are racial differences in incidence and aggressiveness of PCa, which are explained by lifestyle and genetic differences. The incidence of PCa in Caucasian men is 5-10 times higher than that in many regions of Asia. 23 Koreans also have a lower incidence of PCa than Caucasians. However, Korean PCa patients have worse disease characteristics than their American counterparts. 15, 16 Because most of the data regarding %p2PSA and PHI have been based primarily on Western populations, there has been a need to validate these biomarkers in Korean populations. To our best knowledge, our study is the first to examine the performance of %p2PSA and PHI in a cohort of Korean men undergoing their first prostate biopsy. Several previous investigations evaluated %p2PSA and PHI in Asian populations. 24-26 Similar to our findings, they showed superior performance of PHI to tPSA in Asian men.
Early evidence suggests that %p2PSA and PHI may also be able to predict prostate cancer aggressiveness on final histology after radical prostatectomy, as well as on prostate
